X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Everest Medicines will transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan), a first-in-class Trop-2 directed antibody-drug conjugate, in Greater China and South Korea, among Other Asian Markets.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Everest Medicines
Deal Size: $455.0 million Upfront Cash: $280.0 million
Deal Type: Acquisition March 26, 2023
Details:
In single-arm Phase 2 study, Trodelvy demonstrated an ORR of 33.3 percent and a median DoR of 7.7 months, as determined by local assessment, in 108 adult TNBC patients who had previously received a median of three prior systemic therapies in the metastatic setting.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Gilead gains Trodelvy, Immunomedics' lead ADC, is the first ADC the FDA has approved for the treatment of people with metastatic triple-negative breast cancer and is also the first FDA-approved anti-Trop-2 ADC.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $21,000.0 million Upfront Cash: $15,000.0 million
Deal Type: Acquisition October 23, 2020
Details:
Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.
Lead Product(s): Recombinant protein
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: ProteoNic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2020
Details:
Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC).
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2020
Details:
Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM).
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
Acquisition provides Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate that was granted accelerated approval by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $21,000.0 million Upfront Cash: $15,000.0 million
Deal Type: Acquisition September 13, 2020
Details:
Collaboration aims to evaluate Trodelvy in combination with Tecentriq in patients with metastatic urothelial cancer and metastatic non-small cell lung cancer. Roche will be conducting two open-label, randomized Phase 1b/2 studies using its MORPHEUS platform.
Lead Product(s): Sacituzumab Govitecan,Atezolizumab
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2020
Details:
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
